CD44 and breast carcinoma: At least one study has confirmed a putative stem cell phenotype in DTCs [60], and another study has shown that the majority of early DTCs detected in the BM of breast cancer patients with a CD44+/CD24- phenotype correlated with a higher prevalence of bone metastases [61].